Rtw Investments
$11.7B 13F equity value
97 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Rtw Investments covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS INC | 1,993,687 | $1.1B | 9.1% |
| ARGX | ARGENX SE | 709,446 | $658M | 5.6% |
| PTCT | PTC THERAPEUTICS INC | 7,746,415 | $632M | 5.4% |
| PTGX | PROTAGONIST THERAPEUTICS INC | 5,061,175 | $620M | 5.3% |
| CGON | CG ONCOLOGY INC | 8,514,590 | $605M | 5.2% |
| INSM | INSMED INC | 4,842,880 | $516M | 4.4% |
| TNGX | TANGO THERAPEUTICS INC | 13,900,620 | $435M | 3.7% |
| SYRE | SPYRE THERAPEUTICS INC | 4,251,996 | $377M | 3.2% |
| CELC | CELCUITY INC | 3,304,903 | $346M | 3.0% |
| ERAS | ERASCA INC | 17,946,754 | $329M | 2.8% |
Track Rtw Investments's 13F portfolio: $11.7B in reported holdings, 97 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}